PDE1B Activators
Phosphodiesterases (PDEs) are a diverse family of enzymes that play a crucial role in regulating intracellular levels of cyclic nucleotides, specifically cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Among the various PDE isoforms, PDE1B is a subtype that has garnered attention due to its involvement in intracellular signaling cascades. PDE1B activators refer to a class of chemical compounds that specifically modulate the activity of the PDE1B enzyme.
PDE1B, belonging to the calcium/calmodulin-stimulated PDE family, is prominently expressed in tissues such as the brain, heart, and vascular smooth muscle. Activation of PDE1B leads to the hydrolysis of cAMP and cGMP, secondary messengers involved in numerous cellular processes. The physiological consequences of PDE1B activation are multifaceted, influencing cellular responses such as neurotransmission, cardiac contractility, and vascular tone. Consequently, PDE1B activators hold potential as pharmacological tools to selectively manipulate these signaling pathways for research purposes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Icilin | 36945-98-9 | sc-201557 sc-201557A | 10 mg 50 mg | $91.00 $257.00 | 9 | |
Icilin activates transient receptor potential (TRP) channels which can lead to Ca2+ influx, activating PDE1B which is a Ca2+/calmodulin-dependent phosphodiesterase, thus enhancing its functional activity in the signal transduction pathways. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective PDE inhibitor that increases both cAMP and cGMP levels, indirectly enhancing PDE1B activity due to its role in cyclic nucleotide signaling. | ||||||
Papaverine | 58-74-2 | sc-279951 sc-279951A sc-279951B | 10 mg 50 mg 100 mg | $153.00 $265.00 $459.00 | ||
Papaverine is a non-selective PDE inhibitor that leads to increased levels of cAMP and cGMP, which can enhance the activity of PDE1B by increasing the substrate availability for its hydrolytic action. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide inhibits PDE3, leading to elevated cAMP levels, which can activate PDE1B as part of a regulatory mechanism to modulate the levels of cyclic nucleotides, thus enhancing PDE1B's role in signaling. | ||||||
Aminophylline | 317-34-0 | sc-252368 | 25 g | $37.00 | ||
Aminophylline inhibits various PDEs and increases intracellular cAMP and cGMP levels, which can indirectly lead to the activation of PDE1B, enhancing its functional role in signaling pathways. | ||||||
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole is a non-selective PDE inhibitor that increases cAMP and cGMP levels. By increasing the availability of these cyclic nucleotides, PDE1B activity is indirectly enhanced in cellular signaling processes. | ||||||
Theophylline | 58-55-9 | sc-202835 sc-202835A sc-202835B | 5 g 25 g 100 g | $20.00 $32.00 $85.00 | 6 | |
Theophylline, a non-selective PDE inhibitor, raises intracellular levels of cAMP and cGMP, leading to increased PDE1B activity as it works to regulate these cyclic nucleotides within the cell. | ||||||